What is Oppenheimer's price target for SAGE?

Oppenheimer's latest stated price target for Sage Therapeutics Inc. (SAGE) is $80, from its action on Nov 3, 2021.

What is Oppenheimer's rating on SAGE?

Oppenheimer rates SAGE Perform, a neutral rating, as of Aug 7, 2023.

When did Oppenheimer last change its view on SAGE?

On Aug 7, 2023, Oppenheimer downgrades to Perform from Outperform.

Oppenheimer SAGE price target and rating history

Sage Therapeutics Inc. (SAGE) · Health Care

Oppenheimer rates Sage Therapeutics Inc. (SAGE) Perform with a $80 price target, as of its latest action on Aug 7, 2023. It has published 3 rating actions on SAGE since October 2021, including 0 upgrades and 1 downgrade.

Current rating: Perform
Price target: $80
Median target, all firms: Too few
Actions on SAGE: 3

Oppenheimer price target on SAGE

Oppenheimer price target on SAGE, each point a stated target, October 2021 to November 2021.

Every Oppenheimer rating on SAGE

Aug 7, 2023
DowngradeOppenheimer downgrades to Perform from Outperform
Nov 3, 2021
ReiterateOppenheimer cuts its price target to $80 from $84, keeps Outperform
Oct 20, 2021
ReiterateOppenheimer cuts its price target to $84 from $100, keeps Outperform

Questions about Oppenheimer and SAGE

What is Oppenheimer's price target for SAGE?: Oppenheimer's latest stated price target for Sage Therapeutics Inc. (SAGE) is $80, from its action on Nov 3, 2021.
What is Oppenheimer's rating on SAGE?: Oppenheimer rates SAGE Perform, a neutral rating, as of Aug 7, 2023.
When did Oppenheimer last change its view on SAGE?: On Aug 7, 2023, Oppenheimer downgrades to Perform from Outperform.

More SAGE rating histories

All Oppenheimer ratings SAGE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.